anti-thymocyte globulin + sirolimus + tacrolimus

This is a combination immunosuppressive regimen used primarily for prevention of graft-versus-host disease (GVHD) in patients undergoing unrelated hematopoietic stem cell transplantation. The combination works through multiple mechanisms to prevent rejection and GVHD. Anti-thymocyte globulin (ATG) is a polyclonal antibody preparation that targets T cells, leading to T-lymphocyte depletion via complement-mediated cytotoxicity or apoptosis. Sirolimus (also known as rapamycin) inhibits the mammalian target of rapamycin (mTOR), affecting T cell proliferation and can expand regulatory T cells. Tacrolimus prevents T-lymphocyte activation by binding to FK506 binding protein and inhibiting calcineurin. Clinical studies have shown this combination is associated with a low incidence and severity of both acute and chronic GVHD in unrelated donor transplantation.

Other names

Thymoglobulin + sirolimus + tacrolimusATG + sirolimus + tacrolimusrATG + sirolimus + tacrolimus